Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

NCT04624633 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Relapsed Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions

DRUG: Acalabrutinib
DRUG: Umbralisib
DRUG: Ublituximab

Sponsor

Jennifer R. Brown, MD, PhD

Collaborators

[object Object]
[object Object]